Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Advanced Solid Malignancies 1Advanced Rare Malignant Solid Neoplasm 1Advanced Liver Cancers 1

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Rare Malignant Solid Neoplasm × Tiragolumab × 1 year × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡